The Innovative Molecular Analysis Technologies (IMAT) program was established to support the development, technical maturation, and dissemination of novel and potentially transformative next-generation technologies through an approach of balanced but targeted innovation. In support of its mission, the IMAT program utilizes a variety of investigator-initiated research project grant mechanisms while retaining a strong commitment to diversity and to the training of scientists and clinicians in cross-cutting, research-enabling disciplines.
In direct response to Vice President Biden’s Cancer Moonshot, Atlanta-based Global Center for Medical Innovation (GCMI) and T3 Labs are collaborating with the National Cancer Institute (NCI) to accelerate development of innovative diagnostic devices for cancer from the lab to the marketplace. Find out more here.
NIH is seeking ideas for metrics from the community for assessing value of biomedical data repositories. Please follow this link to find out more.
New contract opportunitis around a variety of “hot topics” are issued every summer by the NCI for small business entities. A number of topics specifically target new technology development. Please follow this link to find out more.
The NCI is soliciting U01 applications for improved biomimetic tissue engineering platforms as part of a new cancer tissue engineering collaborative. Multiple due dates starting May 2016 through November 2018. Find out more here..
Small business innovators should consider participating in the National SBIR/STTR conference in Washington DC on May 23-25, 2016, to learn how to engage Federal programs designed to support the commercialization of technological innovations. Consider showcasing your innovations at this broadly attended forum (applications due Feb 5, 2016).
The NCI has issued two new funding opportunities assocated with the Cancer Systems Biology Consortium. Please click the following announcement links for details: Research Centers for Cancer Systems Biology Consortium (U54); Coordinating Center for the Cancer Systems Biology Consortium and the Physical Sciences-Oncology Network (U24).
NCI has issued 4 new grant solicitations for highly innovative informatics technology development research under the Informatics Technologies for Cancer Research program. Various receipt deadlines starting in November, 2015. Please follow this link for more information.
Funding opportunity for Innovative Research in Cancer Nanotechnology
The NCI has a funding opportunity for Innovative Research in Cancer Nanotechnology (IRCN). more+
The NCI has approved reissuance for all R21 and R33 funding opportunity announcements associated with the IMAT program through calendar year 2017. New solicitations are under preparation and links to each will be provided here once available. Anticipated due dates during 2017 will be similar to due dates for the recently expired solicitations. Please use the links below to see prior issuances of the IMAT funding opportunities.
Funding opportunities in technology development are intended to support the inception, maturation, and subsequent dissemination of technically innovative and potentially transformative emerging technologies. These opportunities exist in parallel with various educational and training programs aimed at the recruitment, retention, and promotion of a diverse pool of talent in areas of emerging technology.